|Title:||Ocular implant made by a double extrusion process|
|Abstract:|| The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.|
|Inventor(s):|| Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Atherton, CA), Peng; Lin (South San Francisco, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA) |
|Assignee:|| Allergan, Inc. (Irvine, CA) |
|Filing Date:||Sep 01, 2011|
|Claims:||1. A method for making an ocular bioerodible implant for treating a medical condition of the eye, the method comprising: a) milling a hydrophilic ended poly(D,L-lactide-co-glycolide) (PLGA) polymer; b) milling a hydrophobic ended poly(D,L-lactide-co-glycolide) (PLGA) polymer; c) blending the milled polymers together with particles of dexamethasone to form a blended mixture comprising a hydrophilic ended PLGA, a hydrophobic ended PLGA, and dexamethasone, wherein at least about 75% of the particles of the dexamethasone have a diameter of less than about 20 .mu.m; d) performing a plurality of heat extrusions of the blended mixture, thereby forming a filament including a homogenous distribution of the dexamethasone, wherein the ocular bioerodible implant has a reduced in-batch variability relative to a single extrusion implant. |
2. The method of claim 1, wherein the bioerodible implant is sized for implantation in the vitreous cavity.
3. The method of claim 2, wherein the dexamethasone constitutes from about 10% to about 90% by weight of the implant.
4. The method of claim 3, wherein the dexamethasone constitutes from about 40% to about 80% by weight of the implant.
5. The method of claim 4, wherein the dexamethasone constitutes about 60% by weight of the implant.